TLX Telix Pharmaceuticals Limited
Price Chart
Executive Summary
Telix Pharmaceuticals announced a strategic collaboration with Regeneron to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model. Telix will receive an upfront payment of $40 million and has the option to earn up to $2.1 billion in aggregate milestone payments plus royalties if it opts out of co-funding. The partnership combines Telix’s radiopharmaceutical expertise with Regeneron’s antibody discovery platforms.
Key Financial Metrics
Actionable Insight
The collaboration validates Telix’s platform and de-risks its pipeline through a partnership with a top-tier biotech. Traders should monitor program progression and any opt-in/opt-out decisions on co-funding, which will impact future revenue streams and capital allocation.
Key Facts
- Telix and Regeneron to co-develop and co-commercialize next-generation radiopharmaceuticals in a 50/50 cost and profit-sharing model.
- Telix to receive $40 million upfront from Regeneron for four initial programs.
- If Telix opts out of co-funding for a program, it can earn up to $535 million in milestones per program, with a total potential of $2.1 billion across multiple programs, plus low double-digit royalties.
- Collaboration includes multiple solid tumor targets using Regeneron’s VelocImmune®-derived antibodies and joint development of radio-diagnostic tools.
- Telix retains option to co-promote certain products and will lead commercialization of diagnostic assets.
Financial Impact
$40 million upfront payment received; potential for up to $2.1 billion in milestone payments and low double-digit royalties; 50% share of profits if co-funding is pursued.
Risk Factors
- Execution risk in joint development and regulatory timelines.
- Potential disputes or misalignment with Regeneron on program priorities.
- Uncertainty in achieving clinical and commercial milestones necessary to trigger payments.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272316 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 18, 2026
2d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
May 15, 2026
5d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
May 4, 2026
16d ago
|
Press Release
| $11.04 $10.39 | ▼ −5.89% | ▼ −7.87% | $10.28 (−6.88%) |
|
Apr 29, 2026
21d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
Apr 21, 2026
29d ago
|
Press Release
| $10.33 $10.44 | ▲ +1.06% | ▲ +1.01% | $10.28 (−0.48%) |
|
Apr 13, 2026
5w ago
|
Press Release
| $11.24 $10.73 | ▼ −4.54% | ▼ −7.83% | $10.28 (−8.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access